Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.49 |
| ▸ | ERN1 | O75460 | 7/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20238499 | 1.00 | ESR2 (0.49) | ESR2ERN1AKR1A1AKR1B1DHODH | |
| SCHEMBL3580981 | 0.85 | ESR2 (0.45) | ESR2ERN1AKR1A1AKR1B1ACMSD | |
| SCHEMBL16961907 | 0.81 | ESR2 (0.38) | ESR2AKR1A1AKR1B1DHODHACMSD | |
| SCHEMBL16959836 | 0.81 | ABCC9 (0.38) | ESR2AKR1A1AKR1B1DHODHCYP2D6 | |
| SCHEMBL26345314 | 0.81 | ESR2 (0.35) | ESR2AKR1A1AKR1B1DHODHCYP2D6 | |
| SCHEMBL13602803 | 0.78 | ESR2 (0.43) | ESR2AKR1A1AKR1B1DHODHACMSD | |
| SCHEMBL13453553 | 0.78 | ESR2 (0.43) | ESR2AKR1A1AKR1B1USP30 | |
| SCHEMBL29954261 | 0.77 | ESR2 (0.76) | ESR2ERN1ACMSD | |
| SCHEMBL16055541 | 0.77 | ESR2 (0.76) | ESR2ERN1ACMSD | |
| SCHEMBL28321714 | 0.77 | ESR2 (0.49) | ESR2ERN1ACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638680-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638681-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119638682-A | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-116323598-B | Triazine diketone derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240010639-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-01-11 | — | — | US | disclosed |
| EP-4249474-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022105852-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010639-A1 | TRIAZINE DIONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | MYLK2, TNNT2, TNNC1 | ESR2 4262/4885ERN1 4360/4885AKR1A1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.